Neurol. praxi. 2023;24(3):223-226 | DOI: 10.36290/neu.2023.031
Subcutaneous form of levodopa - new device assisted treatment of Parkinson's disease
- 1 I. neurologická klinika LF MU a FN u sv. Anny v Brně
- 2 Neurologická klinika LF UP a FN Olomouc
- 3 Neurologická klinika 1. LF UK a VFN Praha
More than 50 years since the first clinical use of levodopa there has been no mini-invasive way of administration which would maintain a stable level of levodopa in patients´s body. This has now changed with phosphorylated levodopa, co called phospholevodopa which is soluble in water and therefore can be injected subcutaneously using a pumps. Owing to the subcutaneous application this therapeutic method is expected to spread into clinical practice. The authors summarise the aspects of the development and clinical information of the drug.
Keywords: levodopa, foslevodopa, LCIG, Parkinson's disease, subcutaneous infusion.
Received: March 17, 2023; Revised: May 7, 2023; Accepted: May 11, 2023; Prepublished online: May 11, 2023; Published: June 14, 2023 Show citation
References
- Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson akinesia. Wien Klin Wochenschr. 1961;73:787-8.
- Dorsey ER, et al. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons, DiS. 2018;8(s1):S3-S8.
Go to original source... 
Go to PubMed... - Group P. D.M.C., et al. Long‑term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open‑label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-205. Go to original source... Go to PubMed...
- Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223-236.
- Rosebraugh M, et al. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021;90(1):52-61. Go to original source... Go to PubMed...
- Rosebraugh M, et al. Foslevodopa/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons, DiS. 2021;11(4):16951702.b. Go to original source... Go to PubMed...
- Othman AA, Rosebraugh M, Chatamra K, et al. Levodopa‑carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa‑carbidopa. J Parkinsons, DiS. 2017; 7:275-278. Go to original source... Go to PubMed...
- Rosebraugh M, Stodtmann S, Liu W, et al. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa‑carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord. 2022;97:68-72. Go to original source... Go to PubMed...
- Soileau MJ, Alfred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa‑foscarbidopa in patients wit advanced Parkinson's diseas: a randomised, double‑blind, active‑controlled, phase 3 trial. Lancet Neurol. 2022;21:1099-109. Go to original source... Go to PubMed...
- Wright BA, Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev Neurother. 2013;13(6):719-729. Go to original source... Go to PubMed...